Associated tags: Food and Drug Administration, Food, Health, FDA, Know Labs, Medical Devices, NYSE, Medical device, Research, Diabetes, General Health, Health Technology, Hardware, Biotechnology, Science
Locations: NEW YORK, UNITED STATES, NORTH AMERICA, WASHINGTON, MIDDLE EAST, JAPAN, SOUTH AMERICA, ASIA, NEW ZEALAND, AFRICA, LOUISIANA, NEW ORLEANS, BENCHMARK
Hardware,
General Health,
Health,
Diabetes,
Medical Devices,
Health Technology,
Technology,
Mobile,
Wireless,
SRI International,
Intellectual property,
PARC (company),
Organization,
Intellectual Ventures,
Row,
Palo Alto, California,
Stanford University,
Biomedical engineering,
University,
Diagnosis,
FDA,
Know Labs,
Somogyi,
MBA,
IP,
Incidence,
International,
Medical device Know Labs, Inc. (NYSE American: KNW), an emerging leader in non-invasive medical diagnostic technology, today announced the appointment of Chris Somogyi as President, International.
Key Points:
- Know Labs, Inc. (NYSE American: KNW), an emerging leader in non-invasive medical diagnostic technology, today announced the appointment of Chris Somogyi as President, International.
- In his role, Somogyi will focus on identifying new applications of Know Labs’ extensive intellectual property (IP) portfolio consisting of over 300 patents issued, pending and in-process and covering more than 100 medical and non-medical applications.
- "We are thrilled to welcome Chris Somogyi to our executive team as President, International," said Ron Erickson, CEO and Chairman at Know Labs.
- While the Company moves toward FDA clearance of its technology, Somogyi will work to drive revenue from non-core fields of use of the Know Labs platform technology.
Health Technology,
Health,
Biometrics,
Medical Devices,
Market,
Security (finance),
Burn,
Form 10-K,
Know Labs,
Earnings per share,
Bank statement,
Annual report,
IP,
Research Know Labs, Inc. (NYSE American: KNW), a leading developer of non-invasive medical diagnostic technology, today reported financial results for the second quarter of the fiscal year 2024 ended March 31, 2024.
Key Points:
- Know Labs, Inc. (NYSE American: KNW), a leading developer of non-invasive medical diagnostic technology, today reported financial results for the second quarter of the fiscal year 2024 ended March 31, 2024.
- In Q2 FY 2024, Know Labs reported an operating loss of $4.73 million dollars, compared to an operating loss of $4.81 million dollars in Q2 FY 2023, a reduction in operating loss of 1.7%.
- Research and development expense for Q2 FY 2024 was $2.18 million dollars as compared to $2.56 million dollars in Q2 FY 2023, a decrease of 15.1% year over year.
- Shareholder equity for Q2 FY 2024 was a negative $1.75 million versus $3.74 million in FY 2023, ending September 30, 2023.
Health,
Medical Devices,
Technology,
Clinical Trials,
Research,
Wearables,
Mobile Technology,
Science,
FDA,
Know Labs,
Diabetes,
CGM,
AACE,
Venous blood,
Machine learning,
CDT,
Annual general meeting,
Medical device Know Labs, Inc. (NYSE American: KNW), an emerging developer of non-invasive medical diagnostic technology, today announced it has been selected for an oral abstract presentation at the American Association of Clinical Endocrinology (AACE) Annual Meeting in New Orleans, Louisiana on May 9, 2024 from 11:15 a.m. – 11:30 a.m. CDT.
Key Points:
- Know Labs, Inc. (NYSE American: KNW), an emerging developer of non-invasive medical diagnostic technology, today announced it has been selected for an oral abstract presentation at the American Association of Clinical Endocrinology (AACE) Annual Meeting in New Orleans, Louisiana on May 9, 2024 from 11:15 a.m. – 11:30 a.m. CDT.
- During 2024, as the Company continues on the path toward FDA clearance, Know Labs will deploy the KnowU™, its wearable, non-invasive continuous glucose monitor (CGM) in large-scale, external clinical trials while advancing model techniques and making refinements to the device.
- These new studies will help determine the technology’s performance throughout continuous wear, in more real-world environments, and within more extreme glycemic ranges (below 70 mg/dL and above 350 mg/dL).
- To stay updated on the latest results, visit www.knowlabs.co/research-and-development .
Know Labs, Inc. (NYSE American: KNW), an emerging developer of non-invasive medical diagnostic technology, today announced it will host a webcast to review business updates and results for its second quarter of the fiscal year 2024 ended on March 31, 2024, on May 15, 2024, beginning at 1:30 pm PT.
Key Points:
- Know Labs, Inc. (NYSE American: KNW), an emerging developer of non-invasive medical diagnostic technology, today announced it will host a webcast to review business updates and results for its second quarter of the fiscal year 2024 ended on March 31, 2024, on May 15, 2024, beginning at 1:30 pm PT.
- Media and investors may access the live audio webcast at https://ir.knowlabs.co , beginning at 1:15 pm PT.
- Questions to the Company’s management team can be submitted through the webcast portal during the meeting.
- For more information on Know Labs’ diagnostic platform technology and its progress in developing the first FDA-cleared non-invasive continuous blood glucose monitoring device, visit www.knowlabs.co .
Health,
Medical Devices,
Diabetes,
Biometrics,
Health Technology,
Clinical Trials,
Biotechnology,
CGM,
MARD,
Venous blood,
Know Labs,
Machine,
APS,
Mayo Clinic,
Blood,
American Physiological Society,
FDA Know Labs, Inc. (NYSE American: KNW), an emerging developer of non-invasive medical diagnostic technology, today announced it has been selected for an abstract poster presentation at the American Physiological Society (APS) Summit in Long Beach, California on April 4-7, 2024.
Key Points:
- Know Labs, Inc. (NYSE American: KNW), an emerging developer of non-invasive medical diagnostic technology, today announced it has been selected for an abstract poster presentation at the American Physiological Society (APS) Summit in Long Beach, California on April 4-7, 2024.
- At the previous APS Summit, Know Labs presented results from its peer-reviewed, proof-of-principle study conducted in collaboration with Mayo Clinic, which assessed the accuracy of its RF dielectric sensor in identifying different analytes in vitro, proving a 100% accuracy rate in these tests.
- Since then, Know Labs has published several clinical studies demonstrating the stability, repeatability, and accuracy of its non-invasive continuous blood glucose monitor.
- Most recently, Know Labs announced interim results from its first clinical research protocol involving people with diabetes, using venous blood as a comparative reference and a machine learning model trained on data collected in a lab setting, which resulted in an overall MARD of 11.1%.
Technology,
General Health,
Health,
Hardware,
MARD,
American Diabetes Association,
Algorithm,
CGM,
Know Labs,
Treatment,
FDA,
Blood,
Dielectric spectroscopy,
Data,
Conference,
Type 2 diabetes,
ATTD,
Type 2,
Mayo Clinic,
Clinical professor,
Prediabetes,
Clinical trial,
RF,
CWD,
Medical device Know Labs, Inc. (NYSE American: KNW), an emerging developer of non-invasive medical diagnostic technology, today announced interim results from its most recent clinical research study.
Key Points:
- Know Labs, Inc. (NYSE American: KNW), an emerging developer of non-invasive medical diagnostic technology, today announced interim results from its most recent clinical research study.
- Dr. Virend K. Somers of the Mayo Clinic serves as an author and co-investigator on the clinical research protocol.
- “Despite significant efforts in the development of non-invasive blood glucose monitoring solutions, delivering a highly accurate, economical, FDA-cleared non-invasive continuous glucose monitor (CGM) still remains to be seen.
- On the held-out test dataset, blood glucose was estimated with a MARD of 11.1 ± 2.1% relative to venous blood.
Retrieved on:
Thursday, February 29, 2024
Technology,
Mobile,
Wireless,
Other Professional Services,
Health,
Wearables,
Mobile Technology,
Finance,
Other Health,
Professional Services,
Other Technology,
Medical Devices,
General Health,
Health Technology,
Hardware,
Data Management,
FDA,
Data collection,
Growth,
Partner Ron Erickson, Chief Executive Officer and Chairman at Know Labs, commented, “This investment will enable Know Labs to accelerate development across our four core work streams including, hardware development, expanded data collection in clinical research, algorithm development, and expansion of our defensible intellectual property moat around our technology.
Key Points:
- Ron Erickson, Chief Executive Officer and Chairman at Know Labs, commented, “This investment will enable Know Labs to accelerate development across our four core work streams including, hardware development, expanded data collection in clinical research, algorithm development, and expansion of our defensible intellectual property moat around our technology.
- We remain focused on validating the performance of the Know Labs proprietary radiofrequency dielectric sensor in large-scale clinical trials on our path to submitting to the FDA for clearance, the world’s first non-invasive wearable continuous glucose monitor.”
“Lind is excited about its investment in Know Labs,” said Phillip Valliere, Managing Director at The Lind Partners.
- “Know Labs has demonstrated success across numerous development milestones and has built a strong intellectual property foundation to attract further investment and future strategic partnerships.
- We are pleased to invest in Know Labs to support its growth and we look forward to working with its high-caliber management team as it moves into this next phase of development.”
Retrieved on:
Tuesday, February 27, 2024
Consumer Electronics,
Technology,
Diabetes,
Health,
General Health,
Wearables,
Mobile Technology,
Health Technology,
Medical Devices,
Research,
Science,
Hardware,
Algorithm,
Know Labs,
CGM,
Multimedia,
FDA,
Quality of life,
Dielectric spectroscopy,
Data collection,
Prevalence,
IP,
Glucose,
RF,
Wrist,
Forearm,
Medical device Know Labs , Inc. (NYSE American: KNW), an emerging developer of non-invasive medical diagnostic technology, today announced the KnowU™, its wearable non-invasive continuous glucose monitor (CGM).
Key Points:
- Know Labs , Inc. (NYSE American: KNW), an emerging developer of non-invasive medical diagnostic technology, today announced the KnowU™, its wearable non-invasive continuous glucose monitor (CGM).
- The KnowU brings Know Labs closer to delivering the world’s first non-invasive blood glucose monitor to the global marketplace.
- It records voltage values detected at each frequency to quantify, with trade-secret machine learning algorithms, real-time continuous blood glucose levels.
- During 2024, Know Labs will deploy the KnowU in large-scale, external clinical trials while making refinements to the device and its algorithms.
Retrieved on:
Wednesday, February 14, 2024
Technology,
Health Technology,
Health,
Hardware,
Research,
Burn,
Know Labs,
Form 10-K,
Earnings per share,
Annual report,
Security (finance),
Bank statement,
Cryptocurrency Know Labs, Inc. (NYSE American: KNW), an emerging developer of non-invasive medical diagnostic technology, today reported financial results for the first quarter ended December 31, 2023.
Key Points:
- Know Labs, Inc. (NYSE American: KNW), an emerging developer of non-invasive medical diagnostic technology, today reported financial results for the first quarter ended December 31, 2023.
- In Q1 FY 2024, Know Labs reported a net loss of $3.45 million dollars, compared to a net loss of $3.82 million dollars in Q1 FY 2023, a reduction in net loss of 9.8%.
- Research and development expense for Q1 FY2024 was $1.48 million dollars as compared to $1.74 million dollars in Q1 FY 2023, a decrease of 14.7% year over year.
- Net cash used in operations for Q1 FY 2024 was $3.39 million dollars compared with $2.92 million in Q1 FY 2023.
Retrieved on:
Wednesday, February 7, 2024
Wearables,
Mobile Technology,
Technology,
Research,
Medical Devices,
Diabetes,
Health Technology,
Health,
General Health,
Science,
Know Labs,
Webcast,
FDA Know Labs, Inc. (NYSE American: KNW), an emerging developer of non-invasive medical diagnostic technology, today announced it will host a webcast to review business updates and results for its first quarter of the fiscal year 2024 ended on December 31, 2023, on February 14, 2024, beginning at 1:30 pm PT.
Key Points:
- Know Labs, Inc. (NYSE American: KNW), an emerging developer of non-invasive medical diagnostic technology, today announced it will host a webcast to review business updates and results for its first quarter of the fiscal year 2024 ended on December 31, 2023, on February 14, 2024, beginning at 1:30 pm PT.
- Media and investors may access the live audio webcast at www.knowlabs.co/investors , beginning at 1:15 pm PT.
- Questions to the Company’s management team can be submitted through the webcast portal during the meeting.
- For more information on Know Labs and its progress in developing the first FDA-cleared non-invasive blood glucose monitoring device, visit www.knowlabs.co .
